样本编号	SAMC2518681
外部数据库编号	GSA-Human: HRS512551
样品名称	P34_T2
样本标题	tissue sample of P34
样品类型	Human sample
物种名称	Homo sapiens
描述信息	Target gene sequencing of tissue sample of P34
样本属性	*该样本包含更多受控访问信息，请通过GSA-Human系统申请项目HRA003776数据获取。
发布日期	2024-02-01
项目编号	PRJCA014216
提交者	Zhu Liang (liangzhuwsh@163.com)
提交单位	Affiliated Hospital of Guangdong Medical University
提交日期	2023-06-18

样本包含数据信息

资源名称	描述
GSA-Human (1)	-
HRA003776 (Controlled Access)	The 437panel sequencing of 114 nodules in 36 patients found that EGFR accounted for the largest proportion (55.3%), followed by ERBB2 (9.6%), BRAF, and KRAS (8.8%). Fusion target variation is extremely rare (only 2, 1.8%). ERBB2 Y772_A775dup accounted for 73%, KRAS G12C accounted for about 18%, and BRAF V600E accounted only 10%. ARID1A mutations were significantly higher in invasive adenocarcinoma (IA) containing solid/micro-papillary malignant components (P=0.008). The tumor mutation burden (TMB) distribution is low, with a median TMB of 1.1. In addition, 97.2% of patients (35/36) with MPLC had driver gene mutations, and 47% had co-mutations, mainly in IA (45%) and invasive adenocarcinoma (MIA) (37%) nodule. MPLC has a unique genetic mutation characteristic that differs from advanced patients and usually presents with low TMB.

资源名称

描述

GSA-Human (1)

HRA003776 (Controlled Access)

The 437panel sequencing of 114 nodules in 36 patients found that EGFR accounted for the largest proportion (55.3%), followed by ERBB2 (9.6%), BRAF, and KRAS (8.8%). Fusion target variation is extremely rare (only 2, 1.8%). ERBB2 Y772_A775dup accounted for 73%, KRAS G12C accounted for about 18%, and BRAF V600E accounted only 10%. ARID1A mutations were significantly higher in invasive adenocarcinoma (IA) containing solid/micro-papillary malignant components (P=0.008). The tumor mutation burden (TMB) distribution is low, with a median TMB of 1.1. In addition, 97.2% of patients (35/36) with MPLC had driver gene mutations, and 47% had co-mutations, mainly in IA (45%) and invasive adenocarcinoma (MIA) (37%) nodule. MPLC has a unique genetic mutation characteristic that differs from advanced patients and usually presents with low TMB.